Edition:
United Kingdom

Biofrontera AG (B8FGn.DE)

B8FGn.DE on Xetra

5.88EUR
17 Oct 2018
Change (% chg)

€0.08 (+1.38%)
Prev Close
€5.80
Open
€5.88
Day's High
€5.90
Day's Low
€5.76
Volume
16,126
Avg. Vol
52,657
52-wk High
€7.63
52-wk Low
€2.91

Latest Key Developments (Source: Significant Developments)

Biofrontera: Swissmedic Approves Ameluz In Combination With Daylight Photodynamic Therapy In Switzerland
Monday, 1 Oct 2018 

Oct 1 (Reuters) - BIOFRONTERA AG ::SWISSMEDIC APPROVES AMELUZ(R) IN COMBINATION WITH DAYLIGHT PHOTODYNAMIC THERAPY IN SWITZERLAND.BIOFRONTERA AND LOUIS WIDMER SEE SALES EFFECT FOR SUMMER MONTHS OF 2019 COMPARABLE TO ONE IN GERMAN MARKET THIS YEAR.  Full Article

Deutsche Balaton Biotech: Offer For Biofrontera Shares To Be Carried Out On Schedule
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Deutsche Balaton Biotech AG::Voluntary Purchase Offer For 6.25 Million Biofrontera <<>> SHARES WILL BE CARRIED OUT ON SCHEDULE.DEUTSCHE BALATON AG BIOTECH AG - AS ALREADY ANNOUNCED, VOLUNTARY OFFER ENDS ON 6TH AUGUST 2018.DEUTSCHE BALATON BIOTECH AG - AS ALREADY ANNOUNCED, VOLUNTARY OFFER ENDS ON 6TH AUGUST 2018.  Full Article

Biofrontera Comments On Tender Offer By Deutsche Balaton
Thursday, 2 Aug 2018 

Aug 3 (Reuters) - Biofrontera AG ::Said on Thursday Comments On Tender Offer By Deutsche Balaton.  Full Article

Biofrontera Rejects Modified Tender Offer Of Deutsche Balaton Biotech AG
Monday, 30 Jul 2018 

July 30 (Reuters) - Biofrontera AG ::BIOFRONTERA ALSO REJECTS MODIFIED TENDER OFFER OF DEUTSCHE BALATON BIOTECH AG.  Full Article

Biofrontera: Management To Give Opinion On Changed Purchase Offer
Friday, 27 Jul 2018 

July 27 (Reuters) - BIOFRONTERA AG ::SEES MANAGEMENT TO GIVE OPINION ON CHANGED PURCHASE OFFER AND ALTERNATIVE CONSIDERATION IN AMOUNT OF CASH PAYMENT OF EUR 6.00.  Full Article

Biofrontera Completes Patient Recruitment For Phase III Trial With Ameluz
Thursday, 26 Jul 2018 

July 26 (Reuters) - BIOFRONTERA AG ::EXPANSION OF INDICATION FOR AMELUZ(R): BIOFRONTERA COMPLETES PATIENT RECRUITMENT FOR PHASE III TRIAL.FILING FOR APPROVAL ANTICIPATED FOR Q3 2019.  Full Article

Biofrontera AG Subsidiary Files Suit Against Dusa Pharmaceuticals, Inc
Thursday, 12 Jul 2018 

July 12 (Reuters) - Biofrontera AG ::DGAP-NEWS: BIOFRONTERA AG: BIOFRONTERA AG SUBSIDIARY FILES SUIT AGAINST DUSA PHARMACEUTICALS, INC.  Full Article

Sun Pharmaceutical Unit Files Lawsuit Against Biofrontera For Patent Infringement
Wednesday, 11 Jul 2018 

July 11 (Reuters) - Biofrontera AG ::SUN PHARMACEUTICAL INDUSTRIES LTD - CO'S UNIT, DUSA PHARMACEUTICALS FILES LAWSUIT AGAINST BIOFRONTERA FOR PATENT INFRINGEMENT.SUN PHARMACEUTICAL INDUSTRIES - LAWSUIT ALLEGES PATENT INFRINGEMENT OF DUSA'S PATENTS, US 9,723,991 AND US 8,216,289.  Full Article

Biofrontera And Maruho Consider Continuing Collaboration Under New Agreement
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Biofrontera AG ::DGAP-NEWS: BIOFRONTERA AG: PHASE 1 OF COLLABORATION BETWEEN BIOFRONTERA AND MARUHO COMPLETED.BIOFRONTERA AND MARUHO CURRENTLY CONSIDER CONTINUING THEIR COLLABORATION UNDER A NEW AGREEMENT.  Full Article

Biofrontera Will Be Completing A Voluntary Review Of The February 2018 Share Issuance
Friday, 6 Jul 2018 

July 6 (Reuters) - Biofrontera AG ::DGAP-NEWS: BIOFRONTERA AG: BIOFRONTERA AG WILL BE COMPLETING A VOLUNTARY REVIEW OF THE FEBRUARY 2018 SHARE ISSUANCE.PROVIDED CLARIFICATION IN RESPECT TO ALLEGATIONS MADE BY DEUTSCHE BALATON AG.DISMISSES ALLEGATIONS IN THEIR ENTIRETY.BIOFRONTERA - DECIDED TODAY TO OBTAIN OPINION OF AN UNBIASED SUBJECT-MATTER EXPERT IN ORDER TO COUNTER ACCUSATIONS MADE BY DEUTSCHE BALATON AG.  Full Article